EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Trimeric Class I Viral Fusion Protein Vaccine Immunogens Using a Trimeric Autotransporter in a Killed Whole-Cell Bacteria Vaccine Platform: Applications to HIV MPER

Juan Sebastian Quintero-Barbosa iD, Yufeng Song, Frances Mehl iD, Shubham Mathur iD, Lauren Livingston iD, Xiaoying Shen iD, David C Montefiori, Steven L Zeichner

Viruses · 13.08.2026 · 18 (8) · 890

DOI: 10.3390/v18080890 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, online erschienen am 13.08.2026. Verfasst von Juan Sebastian Quintero-Barbosa und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, University of Virginia, Charlottesville, VA 22908, USA. Hauptthemen laut MEDLINE: AIDS Vaccines, HIV Envelope Protein gp41, HIV-1, HIV Infections. Die Arbeit nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Manning Fund for COVID-19 Research, NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Trimeric envelope-proximal domains in viral class I fusion proteins are conserved targets of broadly neutralizing antibodies (bNAbs), but it has proven difficult to develop vaccines against those targets. The HIV-1 gp41 membrane-proximal external region (MPER) is one such target. Induction of a neutralizing response likely depends on the immunogen having a close-to-native structure.

Methods

Native sequence MPER was displayed on genome-reduced bacteria as a coiled-coil homotrimer using a Haemophilus influenzae Hia trimeric autotransporter. Vaccine designs incorporated additional features, including trimerization domains to stabilize MPER, tandem MPER repeats to increase antigen valency, and immunomodulatory elements. Antigen exposure was assessed by flow cytometry, antibody responses were evaluated by ELISA, and functional activity was measured using HIV-1 pseudovirus neutralization assays.

Results

Trimer stabilization improved MPER exposure, but immunogen visibility alone did not predict neutralization. After three immunizations, neutralizing activity was detected only in the most extensively engineered vaccine, which neutralized tier 2 virus CNE55. After five immunizations, the same vaccine also neutralized the tier 2 virus 25710-2.43. A further design modification that included an extended Hia-derived spacer increased MPER exposure and antibody binding, with neutralization detected against MN.3, X1632_S2_B10, and 25710-2.43 viruses in subsets of animals.

Conclusions

As a proof-of-concept, native-sequence MPER can induce detectable, though modest and virus-dependent, HIV-1 neutralizing activity when displayed in a carefully controlled trimeric bacterial surface-display platform. The results show that MPER vaccine performance depends not only on antigen exposure, but also on multimeric organization, immunomodulatory context, and antigen-scaffold geometry. Analogous coiled-coil trimeric bacterial surface display immunogens may inform vaccine development for stem/stalk regions of other Class I fusion protein viruses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AIDS VaccinesHIV Envelope Protein gp41HIV-1HIV InfectionsViral Fusion ProteinsType V Secretion SystemsAnimalsHIV AntibodiesAntibodies, NeutralizingHumansNeutralization TestsFemaleProtein Subunit VaccinesMiceProtein Multimerization

Stichwörter der Autor:innen

HIV-1Hia autotransporterMPERbroadly neutralizing antibodiesclass I viral fusion protein stalk vaccinegenome-reduced bacteriagp41immunomodulator engineeringkilled whole-cell vaccineneutralizing antibodiesrational vaccine designtrimeric antigen presentation

Substanzen

AIDS VaccinesHIV Envelope Protein gp41HIV AntibodiesAntibodies, NeutralizingViral Fusion ProteinsType V Secretion Systemsgp41 protein, Human immunodeficiency virus 1Protein Subunit Vaccines

Autor:innen und Institutionen

  • Department of Pediatrics, University of Virginia, Charlottesville, VA 22908, USA.
  • Department of Surgery, Duke University, Durham, NC 27710, USA.
  • Duke Human Vaccine Institute, Duke University, Durham, NC 27710, USA.
  • Department of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, VA 22908, USA.

ORCID-Profile: Juan Sebastian Quintero-Barbosa, Frances Mehl, Shubham Mathur, Lauren Livingston, Xiaoying Shen

Förderung

  • Manning Fund for COVID-19 Research
  • NIH HHS
  • NCI NIH HHS
  • Pendleton Laboratory Fund for Pediatric Infectious Disease Research
  • NIAID NIH HHS
  • Ivy Foundation
  • Coulter Foundation
  • NIAID-Duke University contract

Zitieren

APA

Quintero-Barbosa, J. S., Song, Y., Mehl, F., Mathur, S., Livingston, L., Shen, X., Montefiori, D. C., & Zeichner, S. L. (2026). Trimeric Class I Viral Fusion Protein Vaccine Immunogens Using a Trimeric Autotransporter in a Killed Whole-Cell Bacteria Vaccine Platform: Applications to HIV MPER. Viruses, 18(8), 890. https://doi.org/10.3390/v18080890

Vancouver

Quintero-Barbosa JS, Song Y, Mehl F, Mathur S, Livingston L, Shen X, et al. Trimeric Class I Viral Fusion Protein Vaccine Immunogens Using a Trimeric Autotransporter in a Killed Whole-Cell Bacteria Vaccine Platform: Applications to HIV MPER. Viruses. 2026;18(8):890. doi:10.3390/v18080890

BibTeX
@article{QuinteroBarbosa2026,
  author = {Quintero-Barbosa, Juan Sebastian and Song, Yufeng and Mehl, Frances and Mathur, Shubham and Livingston, Lauren and Shen, Xiaoying and Montefiori, David C and Zeichner, Steven L},
  title = {Trimeric Class I Viral Fusion Protein Vaccine Immunogens Using a Trimeric Autotransporter in a Killed Whole-Cell Bacteria Vaccine Platform: Applications to HIV MPER},
  journal = {Viruses},
  year = {2026},
  volume = {18},
  number = {8},
  pages = {890},
  doi = {10.3390/v18080890}
}
Kostenlos starten →